STING1 and neoplasm: Moreover, an engineered E. coli Nissle Strain, SYNB1891.79, expressing STING agonist, demonstrated safety and induced type I IFN-associated pharmacodynamics in tumor and peripheral blood in a phase I trial.80 Therefore, we aimed to evaluate whether MNC-168 modulates STING signaling.